NASDAQ:BLUE - bluebird bio Stock Price, Forecast & News

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio Inc (NASDAQ:BLUE) announced its quarterly earnings data on Thursday, October, 31st. The biotechnology company reported ($3.73) EPS for the quarter, missing analysts' consensus estimates of ($3.54) by $0.19. The biotechnology company earned $8.91 million during the quarter, compared to the consensus estimate of $12.47 million. bluebird bio had a negative net margin of 1,326.56% and a negative return on equity of 42.29%. The business's revenue was down 22.7% on a year-over-year basis. During the same period last year, the business earned ($2.73) EPS. View bluebird bio's Earnings History.

bluebird bio is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for bluebird bio.

18 Wall Street analysts have issued twelve-month price targets for bluebird bio's stock. Their forecasts range from $96.00 to $195.00. On average, they anticipate bluebird bio's share price to reach $138.42 in the next year. This suggests a possible upside of 71.3% from the stock's current price. View Analyst Price Targets for bluebird bio.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 7 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for bluebird bio.

Press coverage about BLUE stock has trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. bluebird bio earned a news impact score of -1.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for bluebird bio.

Some companies that are related to bluebird bio include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Opko Health (OPK), BioMarin Pharmaceutical (BMRN), Celgene (CELG), Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU) and ABIOMED (ABMD).

bluebird bio's stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (2.36%), First Trust Advisors LP (0.79%), Nikko Asset Management Americas Inc. (0.29%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Peregrine Capital Management LLC (0.21%) and California Public Employees Retirement System (0.19%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

BLUE stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Rhenman & Partners Asset Management AB, Voya Investment Management LLC, Great West Life Assurance Co. Can, SG Americas Securities LLC, Metropolitan Life Insurance Co NY, Virginia Retirement Systems ET AL and Benjamin F. Edwards & Company Inc.. Company insiders that have sold bluebird bio company stock in the last year include David Davidson, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Insider Buying and Selling for bluebird bio.

BLUE stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Peregrine Capital Management LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Alberta Investment Management Corp, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Boussard & Gavaudan Investment Management LLP. View Insider Buying and Selling for bluebird bio.

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BLUE stock can currently be purchased for approximately $80.79.

bluebird bio has a market capitalization of $4.47 billion and generates $54.58 million in revenue each year. The biotechnology company earns $-555,630,000.00 in net income (profit) each year or ($10.68) on an earnings per share basis. bluebird bio employs 764 workers across the globe.View Additional Information About bluebird bio.

The official website for bluebird bio is http://www.bluebirdbio.com/.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]